FOR RESEARCH USE ONLY - NOT FOR HUMAN CONSUMPTION.
BPC 157 sequence and specifications begin with a defined 15-residue peptide identity, not a marketing claim. For laboratory buyers, the relevant questions are straightforward: Does the material match the expected sequence? Does the reported mass align with that sequence? Is purity supported by batch-level analytical documentation? And can the supplier provide traceable verification before the material enters a study workflow?
BPC-157 is commonly identified as a synthetic pentadecapeptide with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its one-letter sequence is GEPPPGKPADDAGLV. Published literature has discussed this peptide in preclinical experimental contexts, but those publications do not establish suitability for human use, clinical use, or consumption.
> Compliance Notice
> FOR RESEARCH USE ONLY - NOT FOR HUMAN CONSUMPTION. BPC-157 is supplied exclusively for legitimate laboratory, analytical, and preclinical research purposes. It is not a food, dietary supplement, drug, medical product, or product for administration to humans or animals.
BPC 157 Sequence and Specifications
The BPC-157 sequence contains 15 amino acids and has no disulfide bond requirement. This is analytically relevant because identity confirmation is generally evaluated through methods such as LC-MS or mass spectrometry, alongside chromatographic purity assessment. The expected monoisotopic molecular mass is approximately 1418.73 Da, while the average molecular weight is commonly reported as approximately 1419.53 g/mol. Small differences between reported figures can result from whether a document lists average mass, monoisotopic mass, salt form, hydration state, or instrument-specific reporting conventions.
The commonly cited molecular formula for the free peptide is C62H98N16O22. A specification sheet should state whether the material is supplied as the free peptide, an acetate-associated material, or another defined form. That detail affects how molecular weight and net peptide content are interpreted. A COA that only states “BPC-157” without sequence, analytical method, lot number, and test result provides limited value for a controlled research record.
Core identity profile
| Specification | Reference value |
|---|---|
| Peptide name | BPC-157 |
| Amino acid count | 15 residues |
| One-letter sequence | GEPPPGKPADDAGLV |
| Three-letter sequence | Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val |
| Molecular formula | C62H98N16O22 |
| Average molecular weight | Approximately 1419.53 g/mol |
| Expected identity methods | LC-MS, MS, sequence-confirming analytical methods |
| Purity method | RP-HPLC, reported by area percentage |
These reference values are starting points for incoming-material verification. They are not substitutes for batch-specific test results.
What a Defensible BPC-157 Specification Sheet Includes
For a research peptide, “high purity” is useful only when the claim is defined. A reported value of >99% by HPLC should identify the analytical technique, chromatogram, integration basis, test date, and associated lot. It should also be evaluated alongside identity data. HPLC can demonstrate chromatographic composition, but it does not independently prove that the principal peak is the intended peptide. Mass confirmation closes that gap.
A useful BPC-157 COA typically includes the lot or batch identifier, product name, sequence, molecular weight target, HPLC purity result, LC-MS or MS identity result, date of analysis, and the responsible laboratory or quality unit. For higher-control workflows, researchers may also request residual solvent, water-content, endotoxin, bioburden, heavy-metal, and microbial testing where relevant to their study design. Those tests are not interchangeable, and their relevance depends on the research protocol.
Material handling specifications also need precision. Peptides are commonly supplied as lyophilized material and should be stored according to the supplier’s stated conditions, with temperature exposure, light protection, container integrity, and freeze-thaw handling considered in the laboratory’s internal procedures. Solubility and solution stability are matrix-dependent. They should be established or confirmed under the actual experimental conditions rather than inferred from a generic product listing.
FOR RESEARCH USE ONLY - NOT FOR HUMAN CONSUMPTION.
Research Context for the BPC-157 Peptide
BPC-157 has appeared in published preclinical literature, including experimental work involving cell systems and animal models. The literature is varied in methodology, route of experimental exposure, formulation, comparator selection, and endpoint selection. That variation matters. Results from one model cannot be treated as a general property of the peptide, nor can preclinical observations be translated into claims about people.
Researchers reviewing this literature should separate three questions: whether the tested material was adequately characterized, whether the model and controls were appropriate, and whether the reported endpoint can be reproduced. The peptide sequence alone does not answer any of them. Product quality and study design remain independent variables.
Frequently cited background literature includes Sikiric et al., Current Pharmaceutical Design (2011), DOI: 10.2174/138161211795357645. Researchers may also encounter preclinical publications indexed under the terms “stable gastric pentadecapeptide BPC 157” and “BPC 157 nitric oxide system.” DOI records and full methods sections should be checked directly before using any publication as a protocol rationale or reference standard.
Proposed mechanisms in laboratory models
Published preclinical discussions have examined signaling-related observations involving nitric oxide pathways, vascular-associated signaling, cytoskeletal organization, and gene-expression changes. These are proposed or observed laboratory-model mechanisms, not established mechanisms in humans. Experimental conditions can materially alter peptide behavior, especially where concentration, medium composition, assay duration, peptide integrity, and model selection differ.
For this reason, a technical product page should not turn mechanistic hypotheses into outcome claims. The appropriate statement is narrower: researchers are investigating BPC-157 in defined preclinical systems, and the reported observations require context-specific interpretation and independent replication.
COA Review and Quality Verification
For experienced buyers, the decision point is rarely the listed sequence. It is whether the delivered vial can be connected to supporting data. Before ordering, verify that the supplier can provide a batch-specific COA and that the lot identifier on the document matches the product received. A manufacturer COA is useful, while independent third-party verification adds another layer of confidence when the testing scope and chain of custody are clearly documented.
At Peptide Source, research-grade peptide evaluation is centered on identity, reported purity, controlled production, and documentation review. A stated 99% purity standard should be read as a quality-control threshold supported by the applicable analytical record, not as a substitute for reviewing that record. Buyers should retain COAs with their receiving documentation and record lot information in their study materials log.
The most common quality mistake is treating a generic certificate as batch evidence. A valid report should be specific to the material lot. It should also be internally coherent: the sequence, molecular-weight target, chromatographic result, product form, and sample identifier should not conflict. If a result is unclear, request clarification before assigning the material to an experiment.
Practical Questions From Research Buyers
Is BPC-157 the same as a 15-amino-acid peptide?
Yes. BPC-157 is generally described as a pentadecapeptide, meaning it contains 15 amino-acid residues. Its commonly reported sequence is GEPPPGKPADDAGLV.
What molecular weight should be expected?
The average molecular weight is commonly listed at approximately 1419.53 g/mol for the free peptide. Review the COA for the supplier’s stated form and method because reported mass conventions can differ.
Does >99% HPLC purity confirm identity?
No. HPLC purity and identity are related but distinct quality attributes. A defensible release package includes chromatographic purity data and identity confirmation, such as LC-MS or MS.
Can a generic COA be used for lot verification?
No. Use a batch-specific COA that matches the vial or package lot number. Generic examples are educational documents, not evidence for received material.
How should the lyophilized material be handled?
Follow the storage and handling instructions supplied for the specific lot and apply the laboratory’s approved material-control procedures. Do not use generalized internet protocols as a replacement for validated internal methods.
Is BPC-157 suitable for human or veterinary use?
No. BPC-157 is for research use only and is not for human consumption. It is not supplied for diagnostic, therapeutic, dietary, veterinary, or clinical application.
A reliable BPC-157 purchase decision starts with the sequence but ends with documentation. Confirm the lot, inspect the analytical evidence, and keep the material within a controlled research workflow from receipt through final disposition.
FOR RESEARCH USE ONLY - NOT FOR HUMAN CONSUMPTION.